Skip to content
Clinical Trials – home
SpainBack to Spain

Clinical trials in Marbella – page 22

649 clinical trials in Marbella, Spain across 2 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

SpainOur site in SpainEnsayosClinicos.es(opens in a new tab)
Marbella at a glance
649
clinical trials
  • Research sites2
Type of trial
Recruitment status
Quick filters

649 trials in Marbella

Open in trial search

Cough

Not yet recruiting

Efficacy and Safety of Nalbuphine ER for Reducing Chronic Cough in Adults with Idiopathic Pulmonary Fibrosis (OCEAN-1)

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Nalbuphine Hydrochloride
  • Sponsor:Trevi Therapeutics Inc.

Anaemia+1

Not yet recruiting

Study of Elritercept (TAK‑226) with Ruxolitinib vs Placebo in Patients with Myelofibrosis and Anemia on Ruxolitinib Therapy

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Elritercept
  • Sponsor:Takeda Development Center Americas Inc.

Breast cancer+2

Not yet recruiting

Efficacy and Safety of Letrozole SIE Compared with Oral Letrozole, Both with Ribociclib, in Postmenopausal Women with HR‑Positive, HER2‑Negative Metastatic Breast Cancer

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Letrozole
  • Sponsor:Laboratorios Farmaceuticos Rovi S.A.

Non-small cell lung cancer

Not yet recruiting

Safety and efficacy of rilvegostomig with drug combination in adult patients with unresectable stage III non‑small cell lung cancer undergoing chemoradiotherapy

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:AstraZeneca AB

Allergy test positive

Not yet recruiting

Skin Prick Test Diagnostic Accuracy Study in Patients with Dermatophagoides pteronyssinus and Dermatophagoides farinae Allergy Using Dermatophagoides pteronyssinus Extract and Dermatophagoides farinae Extract

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Sodium Chloride
  • Sponsor:Inmunotek S.L.

Interstitial lung disease+1

Not yet recruiting

Safety and Efficacy of Mirivadelgat Compared with Placebo in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Mirivadelgat
  • Sponsor:Foresee Pharmaceuticals USA Inc.

Study of elranatamab, mezigdomide and dexamethasone in patients with relapsed/refractory multiple myeloma

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Elranatamab
  • Sponsor:Fundacion Pethema

Non-small cell lung cancer+1

Not yet recruiting

Study of setidegrasib (ASP3082) and docetaxel in patients with KRAS G12D‑mutated advanced/metastatic NSCLC after platinum chemo and checkpoint inhibitor

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:ASP3082
  • Sponsor:Astellas Pharma Global Development Inc.

Safety and Efficacy of Extended‑Release Tacrolimus (VI‑0106) in Adults with Pulmonary Arterial Hypertension and Functional Limitations

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Tacrolimus
  • Sponsor:Vivus B.V.

Primary biliary cholangitis

Not yet recruiting

Safety and Efficacy of Saroglitazar Magnesium in Patients with Primary Biliary Cholangitis: A Long‑Term Randomized Placebo‑Controlled Study

Investigational
Countries:SpainSpain
  • Participants:18–64 years
  • Substances:Saroglitazar hemimagnesium
  • Sponsor:Zydus Therapeutics Inc.

Mite allergy

Not yet recruiting

Efficacy and safety of house dust mite allergoid (Dermatophagoides farinae, D. pteronyssinus, aluminium hydroxide) in people with moderate to severe house dust mite allergy

Registered drug
Countries:SpainSpain
  • Participants:0–17 years · 18–64 years
  • Substances:Aluminium Hydroxide
  • Sponsor:Allergopharma GmbH & Co. KG

Ovarian cancer

Not yet recruiting

Phase 2 Study of Trastuzumab Deruxtecan plus Bevacizumab versus Standard Chemotherapy in Patients with Recurrent Ovarian Cancer after PARP Inhibitor Therapy

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Fundacion Grupo Espanol De Investigacion En Cancer Ginecologico

Other cities in Spain

The busiest research cities in the country

All 210 cities in Spain

Clinical research in Marbella

What the registry says about research in the country

01 Oncology Research

Groundbreaking studies focusing on lymphomas and breast cancer treatments, including innovative combination therapies for various stages of disease progression.

  • Mantle Cell Lymphoma
  • HER2-positive Breast Cancer
  • Multiple Myeloma

Advanced clinical trials evaluating novel therapeutic combinations and targeted treatments for improved patient outcomes.

02 Respiratory Medicine

Comprehensive research into pulmonary hypertension and chronic respiratory conditions, testing new therapeutic approaches.

  • Pulmonary Arterial Hypertension
  • COPD Management
  • Asthma Treatment

Evaluation of innovative inhaler technologies and long-term treatment efficacy studies.

03 Infectious Diseases

Studies addressing various infections including herpes simplex and bacterial infections, with focus on treatment optimization.

  • Antiviral Therapies
  • Bacterial Infections
  • Candida Infections

Development of targeted immunotherapies and evaluation of treatment durations for better patient care.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.